Eric M. Dube - 22 Jan 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TVTX
Reported as of: 22 Jan 2025
Net transaction value: -$208,923
SEC form: 4
Accepted by SEC: 23 Jan 2025, 20:39:00 UTC
Prior SEC filing: 09 Sep 2024
Next SEC filing: 04 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 23 Jan 2025.

Key facts

This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jan 2025, 20:39.

Change

Previous filing in this sequence was filed on 09 Sep 2024.
Current net transaction value: -$208,923.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Sale

Transaction value: $208,923
Shares: -10,736
Change %: -3%
Price: $19.46
Shares after: 351,239
Date: 22 Jan 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.